ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: musculoskeletal disease

2022 ACR Guideline for Vaccinations in Patients with RMDs

  |  

This guideline provides evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases. It includes expanded indications for some vaccines, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy.

American College of Rheumatology Benchmark Survey Now in Progress

  |  

This comprehensive study is being conducted to determine benchmarks for rheumatology in an era of increased numbers of uninsured and underinsured patients in the general population, increased chronic and musculoskeletal diseases, and an expanding population of aging citizens.

ACR Research and Education Foundation Meets with NIAMS and AF to Discuss Funding

  |  

The ACR Research and Education Foundation (REF) has been working with the National Institute of Arthritis and Musculoskeletal Diseases (NIAMS) to lead discussions about how to best develop the careers of physician-scientists involved in rheumatic disease research.

I RheumPAC, Do You?

Jim Engelbrecht, MD  |  

For many years, the ACR board of directors and Government Affairs Committee have done exemplary work in keeping members abreast of legislative regulatory issues that affect all aspects of rheumatology, including patient and physician/healthcare professional issues, education, and research. Through advocacy, the ACR advances rheumatology and fosters excellence in the care of people with, or at risk for, arthritis and rheumatic and musculoskeletal diseases. One might say that advocacy is a cornerstone of this organization.

The Great Pediatric Debate—Corticosteroids in SLE: Slay or Stay?

Michael Cammarata, MD, RhMSUS  |  

Long-term use of corticosteroids is associated with numerous adverse effects, particularly in children, but guidance is lacking on how to manage low-dose prednisone in clinically quiescent disease. In The Great Debate at ACR Convergence 2025—Corticosteroids in Pediatric SLE: Slay or Stay, two pediatric lupus experts took to the stage to explore this important topic.